Divarasib plus cetuximab is well tolerated in patients with KRAS G12C-positive colorectal cancer.
Cancer Res (2022) 82 (12_Supplement): 5462.
Cancer Res (2024) 84 (17_Supplement): A006.
1Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 2Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, ...
1Department of Oncology, University of Lausanne, Lausanne, Switzerland.
1Surveillance, Prevention, and Health Services Research, American Cancer Society, Atlanta, Georgia. *Corresponding Author: Elizabeth J. Schafer, Surveillance ...
B cell–depleting therapies impair antibody responses in 2-dose series of mRNA vaccination against SARS-CoV-2, urging research on additional protection against COVID-19 in patients with B-cell ...
1Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France.
Cancer Res (2025) 85 (8_Supplement_1): 6376.
1Lady Davis Institute for Medical Research, SMBD-Jewish General Hospital, McGill University, Montreal, Québec, Canada. 2Departments of Oncology and Medicine, Faculty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback